The Evolving Field of Biomarker Testing in Solid Tumors - Episode 3

PD-L1 Expression and IO Therapy in Lung and Breast Cancer

, , ,

A conversation on PD-L1 biomarker expression in lung cancer, and how it influences treatment with immunotherapy and chemotherapy.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Available Molecular Tests for Solid Tumors
    EP. 2: Using Molecular Testing to Guide Treatment Decisions
    Now Viewing
    EP. 3: PD-L1 Expression and IO Therapy in Lung and Breast Cancer
    EP. 4: Clinical Scenario: A 44-Year-Woman with Metastatic Breast Cancer
    EP. 5: Currently Targetable Mutations in Lung and Breast Cancer
    EP. 6: Choosing a Molecular Testing Panel for Solid Tumors
    EP. 7: Biomarker Testing Interpretation in Breast and Lung Cancer
    EP. 8: Challenges of Biomarker Testing in Breast Cancer
    EP. 9: Use of Liquid Biopsies in Breast Cancer
    EP. 10: Discussing Biomarker Testing with Patients
    EP. 11: Biomarker-Influenced Treatment Approaches for Patients with Metastatic Lung Cancer
    EP. 12: Clinical Scenario: A 74-Year-Old Man with Lung Cancer
    EP. 13: Further Molecular Testing in Early-Stage Metastatic Breast Cancer
    EP. 14: Targeted Therapy in Metastatic Breast Cancer for Patients with BRCA Mutations
    EP. 15: Monitoring Patients on First-Line Treatment for Metastatic Breast Cancer
    EP. 16: Biomarker Testing Standards-of-Care in Breast and Lung Cancer